Cardiovascular Diseases Clinical Trial
To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction.
BACKGROUND:
The study of methods for minimizing the mass of ischemic infarcted myocardium associated
with a myocardial infarction was identified as a topic of research priority in the 1973
Report of the Panel Chairman for the Preparation of the National Heart, Blood Vessel, Lung,
and Blood Program. In September 1976, the Institute convened a workshop involving 32
investigators active in this field, respondents to past solicitations, experts on the topic
of collaborative clinical trials, members of previous review committees, and several members
of the Cardiology Advisory Committee. The attendees were enthusiastic about the practicality
and timeliness of a collaborative clinical trial in this field. The concept of collaborative
clinical trials to protect ischemic myocardium was discussed by the Cardiology Advisory
Committee in its meeting of September 22, 1976, and was recommended affirmatively and
enthusiastically. This trial was part of the Institute's initiatives and was reviewed and
favorably recommended by the National Heart, Lung, and Blood Advisory Council at its
December 1976 meeting. The trial consisted of five clinical centers, six central
laboratories, a clinical coordinating center, and a data coordinating center.
DESIGN NARRATIVE:
Randomized. Group A patients were randomized to propranolol therapy, hyaluronidase therapy,
or control therapy; patients assigned to Group B (propranolol contraindicated) were assigned
to hyaluronidase or control therapy. Single-blind for propranolol therapy, double-blind for
hyaluronidase or control therapy; fixed sample. Detailed follow-up of clinical status and
endpoints for a six-month period; annual health status follow-up thereafter.
The study completion date listed in this record was obtained from the "End Date" entered in
the Query View Report (QVR).
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
| Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
| Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
| Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
| Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
| Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
| Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|